Human insulin tied to elevated lung cancer risk in T2D

  • Front Endocrinol

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Use of human insulin is associated with a dose- and duration-dependent increased risk for lung cancer in patients with type 2 diabetes (T2D).

Why this matters

  • Previous studies on the association between insulin use and lung cancer risk yielded inconsistent results.

Study design

  • 1,007,617 people with T2D enrolled in Taiwan’s National Health Insurance.
  • Funding: Ministry of Science and Technology of Taiwan.

Key results

  • 156,720 had used human insulin (ever-users) and 850,897 had not (never-users).
  • Ever-users had a higher rate of incident lung cancer (1.92% vs 1.61%; 424.45 vs 313.60 per 100,000 person-years).
  • Lung cancer risk was significantly higher among ever-users than never-users (aHR, 1.545; 95% CI, 1.478-1.614).
  • Risk was exacerbated among ever-users with COPD vs non-COPD never-users (HR, 1.891; 95% CI, 1.767-2.024).
  • Lung cancer risk increased with increasing dosage of human insulin (
  • Lung cancer incidence increased with increasing age among ever-users and was highest in age ≥70 years vs

Limitations

  • All-Taiwanese cohort.
  • No data on smoking history.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit